Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Chinese Patent Office
Express Scripts
Chubb
Merck
Daiichi Sankyo
Farmers Insurance
Cantor Fitzgerald
Citi

Generated: October 15, 2018

DrugPatentWatch Database Preview

LYNPARZA Drug Profile

« Back to Dashboard

Which patents cover Lynparza, and what generic alternatives are available?

Lynparza is a drug marketed by Astrazeneca Pharms and is included in two NDAs. There are eight patents protecting this drug.

The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olaparib profile page.

Drug patent expirations by year for LYNPARZA
Generic Entry Opportunity Date for LYNPARZA
Generic Entry Dates for LYNPARZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL
Generic Entry Dates for LYNPARZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for LYNPARZA
Synonyms for LYNPARZA
(2H)-Phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-
09L
1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1
1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine
1(2H)-Phthalazinone, 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-
1021843-02-6
4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2H)-one
4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one
4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one
4-(3-{[4-(Cyclopropylcarbonyl)piperazin-1-Yl]carbonyl}-4-Fluorobenzyl)phthalazin-1(2h)-One
4-[(3-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluoro-phenyl]methyl]-2H-phthalazin-1-one
4-[[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one
4CA-0938
763113-22-0
894104-70-2
937799-91-2
A9666
AB0009952
AB1009702
ABP000423
AC-7939
ACN-032229
Acylpiperazine analogue, 47
AJ-101717
AK-40514
AKOS005145764
AN-493
AN-5279
ANW-43329
AOB1085
API0024518
AX8162101
AZ2281
AZD 2281
AZD 2281|||KU 0059436|||KU 59436
AZD-2281
AZD-2281 (Olaparib)
AZD2281
AZD2281,Olaparib, KU-0059436
AZD2281(olaparib)
AZD2281(olaparib)/AZD-2281/KU0059436
BB 0260909
BC245405
BCP9000363
BCPP000360
BDBM27566
BR-40514
BRD-K02113016-001-08-9
BRD-K02113016-001-09-7
cc-16
CHEBI:83766
CHEMBL521686
CS-0075
CTK8B3857
D09730
D0J9HW
DB09074
EN002690
EX-7210
EX-A002
FDLYAMZZIXQODN-UHFFFAOYSA-N
FT-0083489
FT-0651458
GP0126
GTPL7519
HE068402
HE386863
HMS3654G13
HY-10162
I06-2362
J-503540
KS-00000HXY
KU-0059436
KU-59436
KU0059436
KU59436
Lynparza (TN)
MFCD13185161
MLS006010185
MolPort-009-679-395
NCGC00238451-01
NCGC00238451-02
NSC-747856
NSC747856
Olaparib
Olaparib - AZD2281
Olaparib (AZD2281, Ku-0059436)
Olaparib (AZD2281, KU0059436)
Olaparib (AZD2281)
Olaparib (JAN/USAN/INN)
Olaparib [USAN:INN]
OLAPARIB cpd
Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281
Olaparibum
PubChem19148
QC-2660
RL04905
S-3781
S-7836
s1060
SC-65060
SCHEMBL426568
SMR004701291
SS-4573
UNII-WOH1JD9AR8
WOH1JD9AR8
Z-3275
ZINC40430143

US Patents and Regulatory Information for LYNPARZA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-001 Aug 17, 2017 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-001 Aug 17, 2017 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Astrazeneca Pharms LYNPARZA olaparib CAPSULE;ORAL 206162-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for LYNPARZA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0150012 00136 Estonia ➤ Sign Up PRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014
3 50005-2015 Slovakia ➤ Sign Up PRODUCT NAME: OLAPARIB; REGISTRATION NO/DATE: EU/1/14/959 20141218
680 Luxembourg ➤ Sign Up PRODUCT NAME: OLAPARIB AINSI QUE DES SELS ET DES SOLVATES DE CELUI-CI. FIRST REGISTRATION: 20141218
500012 Hungary ➤ Sign Up PRODUCT NAME: OLAPARIB
2015016,C1633724 Lithuania ➤ Sign Up PRODUCT NAME: OLAPARIBAS IR JO DRUSKOS IR SOLVATAI; REGISTRATION NO/DATE: EU/1/14/959 20141216
/2015 Austria ➤ Sign Up PRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216
90019-4 Sweden ➤ Sign Up PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/14/959 20141218
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Chinese Patent Office
Express Scripts
Chubb
Merck
Daiichi Sankyo
Farmers Insurance
Cantor Fitzgerald
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.